| HOME >> BIOLOGY >> TECHNOLOGY |
About Telavancin Collaboration
In November 2005, Theravance entered into a collaboration arrangement with Astellas Pharma Inc. (Astellas) for the development and commercialization of telavancin worldwide except Japan. In July 2006, Theravance and Astellas expanded the collaboration to include Japan. Under the terms of the collaboration, Theravance will lead the development of telavancin for the treatment of cSSSI and hospital-acquired pneumonia, and will collaborate substantially with Astellas in marketing in the United States for the first three years. Astellas will lead all other development, regulatory, manufacturing, sales and marketing activities.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. Of the five programs
in development, four are in late stage -- its telavancin program focusing
on treating serious Gram-positive bacterial infections with Astellas Pharma
Inc., the Gastrointestinal Motility Dysfunction program, the Beyond Advair
collaboration with GlaxoSmithKline plc and TD-1792 for the treatment of
serious Gram-positive infections. By leveraging its proprietary insight of
multivalency toward drug discovery focused on validated targets, Theravance
is pursuing a next generation strategy designed to discover superior
medicines in large markets. For more information, please visit the
company's web site at
'/>"/>
| SOURCE Astellas Pharma US, Inc. Copyright©2007 PR Newswire. All rights reserved |